PeptideStack
5.2kquestions
20kanswers
220users

Why would PeptideMeter report 97.1% where the supplier certificate says something higher?

Asked 16 Mar 2026Modified 37 days agoViewed 5.6k times
22

Conditions: PeptideMeter · 97.1%.

I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact.

I want to know whether this is recoverable or whether the honest answer is to write it off.

How do I distinguish the benign explanation from the one that matters?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

466 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
shareeditfollowflag
ZM
askedzainab_mustafa16k1716 Mar 2026
2This should probably be in the site help pages rather than buried in an answer. – orla_ferriter 7 months ago
3Good answer, but the confidence interval in the cited trial is wider than implied. – imani_dube 9 months ago
add a comment

4 Answers

Accepted answer first, then by votes
-1

Accepted answer

The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Concretely, buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 23 Jun 2026 by ivo_paunovic — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
IP
answered · acceptedivo_paunovic15k1812 Jun 2026
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
37

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

On the detail: sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
DS
answeredDr_Ravi_Selvarajah42k13823 Jun 2026
3Minor: the trial name is hyphenated in the original publication. – lipid_panel_q 5 months ago
add a comment
28

Reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
DA
answeredDr_Rosalind_Achebe90k15821 May 2026
22

Specifically, identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
TH
answeredtyndall_haze48k481 Jun 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.